Quick Answer
Zentalis Pharmaceuticals, Inc. reported Total Assets of $288.97 million for the year ending 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -32.9% in Total Assets from 2024 to 2025.
- This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $87.63 million | Q2 2020: $257.22 million | Q3 2020: $393.23 million | Q1 2021: $328.35 million | Q2 2021: $283.96 million | Q3 2021: $435.08 million | Q1 2022: $405.68 million | Q2 2022: $567.86 million | Q3 2022: $529.19 million | Q1 2023: $489.34 million | Q2 2023: $621.44 million | Q3 2023: $585.72 million | Q1 2024: $557.48 million | Q2 2024: $491.68 million | Q3 2024: $450.66 million | Q1 2025: $384.02 million | Q2 2025: $351.71 million | Q3 2025: $327.25 million.
- Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Total Assets has grown by 230.3%.
- Historical annual values: Fiscal year 2025: $288.97 million | Fiscal year 2024: $430.34 million | Fiscal year 2023: $551.69 million | Fiscal year 2022: $539.31 million | Fiscal year 2021: $454.51 million | Fiscal year 2020: $365.56 million | Fiscal year 2019: $87.48 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: